comparemela.com

Latest Breaking News On - Trevi therapeutics - Page 6 : comparemela.com

Tracking Ole Andreas Halvorsen's Viking Global Portfolio – Q4 2023 Update

Tracking Ole Andreas Halvorsen's Viking Global Portfolio – Q4 2023 Update
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Bridgebio-pharma
Scott-olson
Lululemon-athletica
Andreas-halvorsen
Bristol-myers-squibb
Newamsterdam-pharma
John-vincent
Amylyx-pharma
Biomarin-pharma
Julian-robertson
Unum-group
Roivant-sciences

Silverarc Capital Management LLC Purchases 41,491 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Silverarc Capital Management LLC lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 927,415 shares of the company’s stock after acquiring an additional 41,491 shares during the […]

California
United-states
Virtu-financial
Silverarc-capital-management
Barclays-plc
Nasdaq
Citigroup-inc
Securities-exchange-commission
Trevi-therapeutics-inc
Trevi-therapeutics
Free-report

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,380,000 shares, an increase of 11.3% from the January 15th total of 1,240,000 shares. Based on an average daily volume of 387,700 shares, the days-to-cover ratio […]

California
United-states
Barclays-plc
Citigroup-inc
Virtu-financial
Trevi-therapeutics-inc
Nasdaq
Trevi-therapeutics
Get-free-report
State-teachers-retirement-system
Trevi-therapeutics-daily

Trevi Therapeutics, Inc. (NASDAQ:TRVI) to Post Q1 2024 Earnings of ($0.09) Per Share, Leerink Partnrs Forecasts

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.09) per share for the quarter. The consensus […]

United-states
American
Leerink-partnrs
Vanguard-group-inc
Deutsche-bank
Trevi-therapeutics-inc
American-century-companies-inc
Nasdaq
Sg-americas-securities
Silverarc-capital-management
Trevi-therapeutics
Free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.